<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38302942</PMID><DateCompleted><Year>2024</Year><Month>02</Month><Day>05</Day></DateCompleted><DateRevised><Year>2024</Year><Month>02</Month><Day>12</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1741-7015</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Feb</Month><Day>02</Day></PubDate></JournalIssue><Title>BMC medicine</Title><ISOAbbreviation>BMC Med</ISOAbbreviation></Journal><ArticleTitle>Substantial health and economic burden of COVID-19 during the year after acute illness among US adults not at high risk of severe COVID-19.</ArticleTitle><Pagination><StartPage>47</StartPage><MedlinePgn>47</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">47</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12916-023-03235-5</ELocationID><Abstract><AbstractText Label="BACKGROUND">Patients recovering from SARS-CoV-2 infection and acute COVID-19 illness can experience a range of long-term post-acute effects. The potential clinical and economic burden of these outcomes in the USA is unclear. We evaluated diagnoses, medications, healthcare utilization, and medical costs before and after acute COVID-19 illness in US patients who were not at high risk of severe COVID-19.</AbstractText><AbstractText Label="METHODS">This study included eligible adults who were diagnosed with COVID-19 from April 1 to May 31, 2020, who were 18&#x2009;-&#x2009;64&#xa0;years of age, and enrolled within Optum's de-identified Clinformatics&#xae; Data Mart Database for 12&#xa0;months before and 13&#xa0;months after COVID-19 diagnosis. Patients with any condition or risk factor placing them at high risk of progression to severe COVID-19 were excluded. Percentages of diagnoses, medications, healthcare utilization, and costs were calculated during baseline (12&#xa0;months preceding diagnosis) and the post-acute phase (12&#xa0;months after the 30-day acute phase of COVID-19). Data were stratified into 3 cohorts according to disposition during acute COVID-19 illness (i.e., not hospitalized, hospitalized without intensive care unit [ICU] admission, or admitted to the ICU).</AbstractText><AbstractText Label="RESULTS">The study included 3792 patients; 56.5% of patients were men, 44% were White, and 94% did not require hospitalization. Compared with baseline, patients during the post-acute phase had percentage increases in the diagnosis of the following disorders: blood (166%), endocrine and metabolic (123%), nervous system (115%), digestive system (76%), and mental and behavioral (75%), along with increases in related prescriptions. Substantial increases in all measures of healthcare utilization were observed among all 3 cohorts. Total medical costs increased by 178% during the post-acute phase. Those who were hospitalized with or without ICU admission during the acute phase had the greatest increases in comorbidities and healthcare resource utilization. However, the burden was apparent across all cohorts.</AbstractText><AbstractText Label="CONCLUSIONS">As evidenced by resource use in the post-acute phase, COVID-19 places a significant long-term clinical and economic burden among US individuals, even among patients whose acute infection did not merit hospitalization.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Scott</LastName><ForeName>Amie</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Global Real World Evidence, Pfizer Inc, 235 East 42nd Street, New York, NY, 10017, USA. Amie.scott@pfizer.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ansari</LastName><ForeName>Wajeeha</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Global HEOR, Pfizer Inc, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chambers</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Global Product Development Statistics, Pfizer Inc, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reimbaeva</LastName><ForeName>Maya</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Global Biometrics and Data Management, Pfizer Inc, Groton, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mikolajczyk</LastName><ForeName>Tomasz</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>, Quanticate, Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benigno</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Global Real World Evidence, Pfizer Inc, 235 East 42nd Street, New York, NY, 10017, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Draica</LastName><ForeName>Florin</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Medical Affairs, Pfizer Inc, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Atkinson</LastName><ForeName>Joanna</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Medical Affairs, Pfizer Ltd, Tadworth, Surrey, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>02</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Med</MedlineTA><NlmUniqueID>101190723</NlmUniqueID><ISSNLinking>1741-7015</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086522" MajorTopicYN="N">Financial Stress</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086742" MajorTopicYN="N">COVID-19 Testing</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">PASC</Keyword><Keyword MajorTopicYN="N">Post-COVID conditions</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList><CoiStatement>AS, WA, RC, MR, MB, FD, and JA are employees of Pfizer Inc and may hold stock or stock options. TM is an employee of Quanticate, which receives consulting fees from Pfizer Inc.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>2</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>12</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>2</Month><Day>5</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>2</Month><Day>2</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>2</Month><Day>2</Day><Hour>0</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>2</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38302942</ArticleId><ArticleId IdType="pmc">PMC10835856</ArticleId><ArticleId IdType="doi">10.1186/s12916-023-03235-5</ArticleId><ArticleId IdType="pii">10.1186/s12916-023-03235-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bull-Otterson L, Baca S, Saydah S, Boehmer TK, Adjei S, Gray S, et al. Post-COVID conditions among adult COVID-19 survivors aged 18&#x2013;64 and &#x2265;65 years &#x2014; United States, March 2020&#x2013;November 2021. MMWR Morb Mortal Wkly Rep. 2022;71(21):713&#x2013;717. doi: 10.15585/mmwr.mm7121e1.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7121e1</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention. Nearly One in Five American Adults Who Have Had COVID-19 Still Have "Long COVID". Available at: https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2022/20220622.htm. Accessed 6 Sept 2022.</Citation></Reference><Reference><Citation>World Health Organization. A Clinical Case Definition of Post COVID-19 Condition by a Delphi Consensus. World Health Organization. Available at: https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1. Accessed 8 Jun 2022.</Citation></Reference><Reference><Citation>Amenta EM, Spallone A, Rodriguez-Barradas MC, El Sahly HM, Atmar RL, Kulkarni PA. Postacute COVID-19: an overview and approach to classification. Open Forum Infect Dis. 2020;7(12):ofaa509. doi: 10.1093/ofid/ofaa509.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofaa509</ArticleId><ArticleId IdType="pmc">PMC7665635</ArticleId><ArticleId IdType="pubmed">33403218</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention. Post-COVID Conditions: Information for Healthcare Providers. Available at: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-conditions.html. Accessed 23 Jun 2022.</Citation></Reference><Reference><Citation>Davis HE, Assaf GS, McCorkell L, Wei H, Low RJ, Re'em Y, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021;38:101019. doi: 10.1016/j.eclinm.2021.101019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101019</ArticleId><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention. New ICD-10-CM Code for Post-COVID Conditions, Following the 2019 Novel Coronavirus (COVID-19). Centers for Disease Control and Prevention. Available at: https://www.cdc.gov/nchs/data/icd/Announcement-New-ICD-code-for-Post-COVID-Condition-April-2022-final.pdf. Accessed 8 Jun 2022.</Citation></Reference><Reference><Citation>McGrath LJ, Scott AM, Surinach A, Chambers R, Benigno M, Malhotra D. Use of the post-acute sequelae of COVID-19 diagnosis code in routine clinical practice in the US. JAMA Netw Open. 2022;5(5):e2235089. doi: 10.1001/jamanetworkopen.2022.35089.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.35089</ArticleId><ArticleId IdType="pmc">PMC9539719</ArticleId><ArticleId IdType="pubmed">36201207</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention. Underlying Medical Conditions Associated With Higher Risk for Severe COVID-19: Information for Healthcare Professionals. Available at: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html. Accessed 9 Jan 2022.</Citation><ArticleIdList><ArticleId IdType="pubmed">34009770</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, et al. Attributes and predictors of long COVID. Nat Med. 2021;27(4):626&#x2013;631. doi: 10.1038/s41591-021-01292-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01292-y</ArticleId><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai F, Tomasoni D, Falcinella C, Barbanotti D, Castoldi R, Mule G, et al. Female gender is associated with long COVID syndrome: a prospective cohort study. Clin Microbiol Infect. 2022;28(4):611.e619&#x2013;611.e616. doi: 10.1016/j.cmi.2021.11.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2021.11.002</ArticleId><ArticleId IdType="pmc">PMC8575536</ArticleId><ArticleId IdType="pubmed">34763058</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoo SM, Liu TC, Motwani Y, Sim MS, Viswanathan N, Samras N, et al. Factors associated with post-acute sequelae of SARS-CoV-2 (PASC) after diagnosis of symptomatic COVID-19 in the inpatient and outpatient setting in a diverse cohort. J Gen Intern Med. 2022;37(8):1988&#x2013;1995. doi: 10.1007/s11606-022-07523-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11606-022-07523-3</ArticleId><ArticleId IdType="pmc">PMC8989256</ArticleId><ArticleId IdType="pubmed">35391623</ArticleId></ArticleIdList></Reference><Reference><Citation>Groff D, Sun A, Ssentongo AE, Ba DM, Parsons N, Poudel GR, et al. Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection: a systematic review. JAMA Netw Open. 2021;4(10):e2128568. doi: 10.1001/jamanetworkopen.2021.28568.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.28568</ArticleId><ArticleId IdType="pmc">PMC8515212</ArticleId><ArticleId IdType="pubmed">34643720</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen MS, Kristiansen MF, Hanusson KD, Danielsen ME, B AS, Gaini S, et al. Long COVID in the Faroe Islands: a longitudinal study among nonhospitalized patients. Clin Infect Dis. 2021;73(11):e4058&#x2013;e4063. doi: 10.1093/cid/ciaa1792.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa1792</ArticleId><ArticleId IdType="pmc">PMC7799340</ArticleId><ArticleId IdType="pubmed">33252665</ArticleId></ArticleIdList></Reference><Reference><Citation>Augustin M, Schommers P, Stecher M, Dewald F, Gieselmann L, Gruell H, et al. Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study. Lancet Reg Health Eur. 2021;6:100122. doi: 10.1016/j.lanepe.2021.100122.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2021.100122</ArticleId><ArticleId IdType="pmc">PMC8129613</ArticleId><ArticleId IdType="pubmed">34027514</ArticleId></ArticleIdList></Reference><Reference><Citation>Chenchula S, Karunakaran P, Sharma S, Chavan M. Current evidence on efficacy of COVID-19 booster dose vaccination against the Omicron variant: a systematic review. J Med Virol. 2022;94(7):2969&#x2013;2976. doi: 10.1002/jmv.27697.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27697</ArticleId><ArticleId IdType="pmc">PMC9088621</ArticleId><ArticleId IdType="pubmed">35246846</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao H, Lu L, Peng Z, Chen LL, Meng X, Zhang C, et al. SARS-CoV-2 Omicron variant shows less efficient replication and fusion activity when compared with Delta variant in TMPRSS2-expressed cells. Emerg Microbes Infect. 2022;11(1):277&#x2013;283. doi: 10.1080/22221751.2021.2023329.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2021.2023329</ArticleId><ArticleId IdType="pmc">PMC8774049</ArticleId><ArticleId IdType="pubmed">34951565</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdullah F, Myers J, Basu D, Tintinger G, Ueckermann V, Mathebula M, et al. Decreased severity of disease during the first global Omicron variant COVID-19 outbreak in a large hospital in Tshwane. South Africa Int J Infect Dis. 2022;116:38&#x2013;42. doi: 10.1016/j.ijid.2021.12.357.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2021.12.357</ArticleId><ArticleId IdType="pmc">PMC8713416</ArticleId><ArticleId IdType="pubmed">34971823</ArticleId></ArticleIdList></Reference><Reference><Citation>Meo SA, Meo AS, Al-Jassir FF, Klonoff DC. Omicron SARS-CoV-2 new variant: global prevalence and biological and clinical characteristics. Eur Rev Med Pharmacol Sci. 2021;25(24):8012&#x2013;8018.</Citation><ArticleIdList><ArticleId IdType="pubmed">34982465</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott A, Ansari W, Khan F, Chambers R, Benigno M, Di Fusco M, et al. Substantial health and economic burden of COVID&#x2011;19 during the year after acute illness among US adults at high risk of severe COVID&#x2011;19. BMC Med. 2022. 10.1186/s12916-023-03234-6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10836000</ArticleId><ArticleId IdType="pubmed">38303065</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretorius E, Vlok M, Venter C, Bezuidenhout JA, Laubscher GJ, Steenkamp J, et al. Persistent clotting protein pathology in long COVID/post-acute sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin. Cardiovasc Diabetol. 2021;20(1):172. doi: 10.1186/s12933-021-01359-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-021-01359-7</ArticleId><ArticleId IdType="pmc">PMC8381139</ArticleId><ArticleId IdType="pubmed">34425843</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamontagne SJ, Winters MF, Pizzagalli DA, Olmstead MC. Post-acute sequelae of COVID-19: evidence of mood &amp; cognitive impairment. Brain Behav Immun Health. 2021;17:100347. doi: 10.1016/j.bbih.2021.100347.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbih.2021.100347</ArticleId><ArticleId IdType="pmc">PMC8437695</ArticleId><ArticleId IdType="pubmed">34549199</ArticleId></ArticleIdList></Reference><Reference><Citation>Houben-Wilke S, Goertz YM, Delbressine JM, Vaes AW, Meys R, Machado FV, et al. The impact of long COVID-19 on mental health: observational 6-month follow-up study. JMIR Ment Health. 2022;9(2):e33704. doi: 10.2196/33704.</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/33704</ArticleId><ArticleId IdType="pmc">PMC8914795</ArticleId><ArticleId IdType="pubmed">35200155</ArticleId></ArticleIdList></Reference><Reference><Citation>Utrero-Rico A, Ruiz-Ruigomez M, Laguna-Goya R, Arrieta-Ortubay E, Chivite-Lacaba M, Gonzalez-Cuadrado C, et al. A short corticosteroid course reduces symptoms and immunological alterations underlying long-COVID. Biomedicines. 2021;9(11):1540. doi: 10.3390/biomedicines9111540.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines9111540</ArticleId><ArticleId IdType="pmc">PMC8614904</ArticleId><ArticleId IdType="pubmed">34829769</ArticleId></ArticleIdList></Reference><Reference><Citation>Samprathi M, Jayashree M. Biomarkers in COVID-19: an up-to-date review. Front Pediatr. 2020;8:607647. doi: 10.3389/fped.2020.607647.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fped.2020.607647</ArticleId><ArticleId IdType="pmc">PMC8042162</ArticleId><ArticleId IdType="pubmed">33859967</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel MA, Knauer MJ, Nicholson M, Daley M, Van Nynatten LR, Martin C, et al. Elevated vascular transformation blood biomarkers in long-COVID indicate angiogenesis as a key pathophysiological mechanism. Mol Med. 2022;28(1):122. doi: 10.1186/s10020-022-00548-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s10020-022-00548-8</ArticleId><ArticleId IdType="pmc">PMC9549814</ArticleId><ArticleId IdType="pubmed">36217108</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonelli M, Penfold RS, Merino J, Sudre CH, Molteni E, Berry S, et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. Lancet Infect Dis. 2022;22(1):43&#x2013;55. doi: 10.1016/S1473-3099(21)00460-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00460-6</ArticleId><ArticleId IdType="pmc">PMC8409907</ArticleId><ArticleId IdType="pubmed">34480857</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M, Dercon Q, Harrison PJ. Six-month sequelae of post-vaccination SARS-CoV-2 infection: a retrospective cohort study of 10,024 breakthrough infections. Brain Behav Immun. 2022;103:154&#x2013;162. doi: 10.1016/j.bbi.2022.04.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2022.04.013</ArticleId><ArticleId IdType="pmc">PMC9013695</ArticleId><ArticleId IdType="pubmed">35447302</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Choi T, Al-Aly Z. Nirmatrelvir and the risk of post-acute sequelae of COVID-19. medRxiv. Preprint posted online November 5, 2022. 10.1101/2022.11.03.22281783.</Citation></Reference><Reference><Citation>Peluso MJ, Anglin K, Durstenfeld MS, Martin JN, Kelly JD, Hsue PY, et al. Effect of oral nirmatrelvir on long COVID symptoms: 4 cases and rationale for systematic studies. Pathog Immun. 2022;7(1):95&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9254867</ArticleId><ArticleId IdType="pubmed">35800257</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>